Molecular and Functional Characterization of Human Intestinal Organoids and Monolayers for Modeling Epithelial Barrier.

Autor: Jelinsky SA; Pfizer Worldwide Research, Development, and Medical, Cambridge, MA, USA., Derksen M; HUB Organoids, Utrecht, the Netherlands., Bauman E; Pfizer Worldwide Research, Development, and Medical, Cambridge, MA, USA., Verissimo CS; HUB Organoids, Utrecht, the Netherlands., van Dooremalen WTM; HUB Organoids, Utrecht, the Netherlands., Roos JL; HUB Organoids, Utrecht, the Netherlands., Higuera Barón C; HUB Organoids, Utrecht, the Netherlands., Caballero-Franco C; Pfizer Worldwide Research, Development, and Medical, Cambridge, MA, USA., Johnson BG; Pfizer Worldwide Research, Development, and Medical, Cambridge, MA, USA., Rooks MG; Pfizer Worldwide Research, Development, and Medical, Cambridge, MA, USA., Pott J; HUB Organoids, Utrecht, the Netherlands., Oldenburg B; Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands., Vries RGJ; HUB Organoids, Utrecht, the Netherlands., Boj SF; HUB Organoids, Utrecht, the Netherlands., Kasaian MT; Pfizer Worldwide Research, Development, and Medical, Cambridge, MA, USA., Pourfarzad F; HUB Organoids, Utrecht, the Netherlands., Rosadini CV; Pfizer Worldwide Research, Development, and Medical, Cambridge, MA, USA.

Publikováno v: Inflammatory bowel diseases [Inflamm Bowel Dis] 2023 Feb 01; Vol. 29 (2), pp. 195-206.

Anti-IL-13Rα2 therapy promotes recovery in a murine model of inflammatory bowel disease.

Autor: Karmele EP; Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.; Institute for Biomedical Sciences, The George Washington University, Washington, DC, USA., Pasricha TS; Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Ramalingam TR; Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Thompson RW; Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Gieseck RL 3rd; Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.; Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA., Knilans KJ; Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Hegen M; Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA., Farmer M; Biomedicine Design, Pfizer Inc., Cambridge, MA, USA., Jin F; Biomedicine Design, Pfizer Inc., Cambridge, MA, USA., Kleinman A; 23andMe, Mountain View, CA, USA., Hinds DA; 23andMe, Mountain View, CA, USA., Almeida Pereira T; Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., de Queiroz Prado R; Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.; Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA., Bing N; Human Genetics, Pfizer Inc., Cambridge, MA, USA., Tchistiakova L; Biomedicine Design, Pfizer Inc., Cambridge, MA, USA., Kasaian MT; Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA., Wynn TA; Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.; Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA., Vannella KM; Immunopathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. kevin.vannella@nih.gov.

Publikováno v: Mucosal immunology [Mucosal Immunol] 2019 Sep; Vol. 12 (5), pp. 1174-1186. Date of Electronic Publication: 2019 Jul 15.

Proteomic analysis of serum and sputum analytes distinguishes controlled and poorly controlled asthmatics.

Autor: Kasaian MT; Inflammation and Immunology Research Unit, Pfizer, Cambridge, Massachusetts, USA., Lee J; Early Clinical Development, Pfizer, Cambridge, Massachusetts, USA., Brennan A; Inflammation and Immunology Research Unit, Pfizer, Cambridge, Massachusetts, USA., Danto SI; Inflammation and Immunology Research Unit, Pfizer, Cambridge, Massachusetts, USA., Black KE; Department of Medicine, University of Vermont, Burlington, Vermont, USA., Fitz L; Early Clinical Development, Pfizer, Cambridge, Massachusetts, USA., Dixon AE; Department of Medicine, University of Vermont, Burlington, Vermont, USA.

Publikováno v: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology [Clin Exp Allergy] 2018 Jul; Vol. 48 (7), pp. 814-824. Date of Electronic Publication: 2018 May 15.

Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA⁺ B cells.

Autor: Xie, Ying^1,2 (AUTHOR), Huang, Yu^1,2 (AUTHOR), Li, Zhi-Yong^1,2 (AUTHOR), Jiang, Weihua^1,2 (AUTHOR), Shi, Nan-Xi^1,2 (AUTHOR), Lu, Yuanzhi³ (AUTHOR), Cao, Guangchao^1,2 (AUTHOR), Yin, Zhinan^1,2 (AUTHOR) tzhinan@jnu.edu.cn, Lin, Xue-Jia^1,2 (AUTHOR) seta1988@126.com

Publikováno v: Molecular Cancer. 5/8/2024, Vol. 23 Issue 1, p1-15. 15p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.